الفهرس 
IntroductionOnly 14 pages are availabe for public view
 |  | from | 116 |  |  |
| | | from | 116 | | |
Abstract
Female sexual dysfunction is more complicated and significantly less is understood in comparison to male sexual dysfunction. Currently, female sexual disorders are conceptualized as disturbances in desire, arousal, or orgasm as well as sexual pain disorders which include dyspareunia and vaginismus. At the present time, hypoactive sexual desire disorder is the most commonly diagnosed female sexual disorder followed by female orgasmic disorder.
A central player in behavioral states, including sexual function, is a dopamine signals through its receptors (D1, D2, D3, D4, and D5). It was found that dopamine agonists, apomorphine and bupropion, used in the treatment of Parkinson‘s disease, have displayed mixed results in increasing sexual function in both males and females.
Additionally, dopamine is involved in the interaction between ovarian hormones and neuronal excitability in the ventromedial hypothalamus via an intersection of dopamine-triggered biochemical pathways with receptors for progesterone in these cells. Moreover, sexual desire appears to be controlled by a dopamine-sensitive excitatory center, in balance with a serotonin-sensitive inhibitory center. In both males and females, testosterone is responsible for programming these centers.
The aim of this study was to assess prevalence of FSD and its possible risk factors, in addition to investigate the possible role of dopamine in FSD through analysis of dopamine, estrogen, progesterone and DHEA serum levels in females complaining from sexual dysfunction.
To elucidate our aim, all included women completed a questionnaire, regarding the socio-demographic data and reproductive data as well as FSFI. from the studied females, we selected 200 females; 100 females having FSD (patient group) and 100 females without FSD (control group). For these selected females, dopamine, estradiol, progesterone and DHEA serum levels were measured.